Allergan 100 Vials - Allergan Refresh Plus Lubricant Eye Drops Single-Use Vials - 100 Ct.

Product Information

Side effects related to the cornea (the surface of the eye) may be more likely if ACULAR is used for longer than two weeks or if you are using topical steroid drops at the same time or if you have a related eye condition. You should see your doctor immediately if you experience pain, increased irritation in the eye or changes in vision.

XEN ® Gel Stent complications may include choroidal effusion, hyphema, hypotony, implant migration, implant exposure, wound leak, need for secondary surgical intervention, and intraocular surgery complications. Safety and effectiveness in neovascular, congenital, and infantile glaucoma has not been established. Avoid digital pressure following implantation of the XEN ® Gel Stent to avoid the potential for implant damage. Still, Dr. Massaro-Gordon says all of these recalls should cause people to be extra aware of what they’re purchasing. “Patients and doctors have to do their research to make sure eye drops they’re considering aren’t on the FDA’s list,” she says. LUMIGAN has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.Additionally, Harvard Drug Group LLC also initiated a voluntary nationwide recall for all lots of two Rugby Laboratories brand eye drops. Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Purely Soothing 15% MSM Drops, LOT#: 2203PS01, UPC 7 31034 91379 9; and LOT#: 1808051, UPC 7 31034 91382 9. Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. Many of the infections linked to eye drops are of the cornea, Zimmerman says. He says to look out for the following symptoms:

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA ® intracameral implant. DURYSTA ® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. abnormal sensation in the eye, iris inflammation, swollen conjunctiva (see-through layer of the eye), painful eyelids, tired eyes, in-growing eyelashes, darkening of iris colour, eyes appear sunken, eyelid drooping, eyelid shrinking (moving away from the surface of the eye leading to incomplete closure of the eyelids),skin tightness of the eyelids, darkening of eyelashes.DURYSTA ® should be used with caution in patients with narrow iridocorneal angles (Shaffer grade ˂ 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache. Prostaglandin analogs, including DURYSTA ®, have been reported to cause intraocular inflammation. DURYSTA ® should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated. known risk factors for macular oedema (swelling of the retina within the eye leading to worsening vision), for example, cataract surgery These drops were recalled after two lots were found to not be sterile. No illnesses have been tied to the recall so far. These codes were part of the recall:

FAQs

cystoid macular oedema (swelling of the retina within the eye leading to worsening vision), eye swelling, blurred vision, ocular discomfort. Increased IOP with OZURDEX ® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX ® required surgical procedures for management of elevated IOP. Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. In addition, because these products may exacerbate inflammation, caution should be used in patients with active intraocular inflammation (e.g., uveitis). As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.